These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23902545)

  • 21. Drug-induced lupus: an update on its dermatologic aspects.
    Marzano AV; Vezzoli P; Crosti C
    Lupus; 2009 Oct; 18(11):935-40. PubMed ID: 19762393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of refractory cutaneous lupus erythematosus.
    Duna GF; Cash JM
    Rheum Dis Clin North Am; 1995 Feb; 21(1):99-115. PubMed ID: 7732177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the management of cutaneous lupus erythematosus.
    Callen JP
    Br J Dermatol; 2004 Oct; 151(4):731-6. PubMed ID: 15491411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thalidomide and thrombosis].
    Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
    Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Ro antibodies and neonatal lupus.
    Petri M; Watson R; Hochberg MC
    Rheum Dis Clin North Am; 1989 May; 15(2):335-60. PubMed ID: 2657894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-α antagonists and rituximab therapy?
    Lis-Święty A; Brzezińska-Wcisło L; Widuchowska M; Kucharz E
    Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):443-6. PubMed ID: 23537059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus.
    Zampieri S; Alaibac M; Iaccarino L; Rondinone R; Ghirardello A; Sarzi-Puttini P; Peserico A; Doria A
    Ann Rheum Dis; 2006 Apr; 65(4):545-8. PubMed ID: 16096331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy.
    Kreuter A; Tomi NS; Weiner SM; Huger M; Altmeyer P; Gambichler T
    Br J Dermatol; 2007 Jun; 156(6):1321-7. PubMed ID: 17408395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous lupus erythematosus and cardiolipin antibodies. Incidence and clinical significance].
    Kind P; Schuppe HC; Jung KP; Degitz K; Lakomek HJ; Goerz G
    Hautarzt; 1992 Mar; 43(3):126-9. PubMed ID: 1577599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous lupus erythematosus: recent lessons from animal models.
    Ghoreishi M; Dutz JP
    Lupus; 2010 Aug; 19(9):1029-35. PubMed ID: 20693196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The disease with the butterfly. 2nd International Congress for Cutaneous Lupus Erythematosus in Kyoto, Japan, May 11-13, 2008].
    Lehmann P; Ruzicka T
    Hautarzt; 2008 Jul; 59(7):591-3. PubMed ID: 18553184
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide.
    Llambrich A; Romero D; Iranzo P; Segura S; Moreno JA; Herrero C
    J Eur Acad Dermatol Venereol; 2007 Jan; 21(1):136-7. PubMed ID: 17207199
    [No Abstract]   [Full Text] [Related]  

  • 33. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies.
    Lee HJ; Sinha AA
    Autoimmunity; 2006 Sep; 39(6):433-44. PubMed ID: 17060022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.
    Briani C; Zara G; Rondinone R; Iaccarino L; Ruggero S; Toffanin E; Ermani M; Ghirardello A; Zampieri S; Sarzi-Puttini P; Doria A
    Autoimmunity; 2005 Nov; 38(7):549-55. PubMed ID: 16373260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus.
    Albrecht J; Werth VP
    Dermatol Ther; 2007; 20(2):93-101. PubMed ID: 17537137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide treatment for hypertrophic cutaneous lupus erythematosus.
    Gambini D; Carrera C; Passoni E; Muratori S; Berti E; Caputo R
    J Dermatolog Treat; 2004 Dec; 15(6):365-71. PubMed ID: 15764048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A database analysis of cutaneous lupus erythematosus with the EUSCLE Core Set Questionnaire.
    Meuth AM; Amler S; Haust M; Bein D; Sauerland C; Köpcke W; Bonsmann G; Nyberg F; Kuhn A
    Acta Derm Venereol; 2010 Jul; 90(4):386-94. PubMed ID: 20574604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus.
    Abe M; Shimizu A; Yokoyama Y; Takeuchi Y; Ishikawa O
    Clin Exp Dermatol; 2008 Nov; 33(6):759-63. PubMed ID: 18713254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Manifestations and treatment of cutaneous lupus erythematosus (part I of II).
    Schairer D; Friedman A
    J Drugs Dermatol; 2011 Oct; 10(10):1212-4. PubMed ID: 21968677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.